Celcuity Inc. (NASDAQ:CELC) stock surged on Monday after the company reported topline results from the PIK3CA wild-type ...

We recently published These 10 Stocks are Winning Big. Celcuity Inc. (NASDAQ:CELC) is one of the best-performing stocks on ...

Celcuity shares skyrocketed to an all-time high when the biotech reported positive results from a Phase 3 trial of its ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...

Sara Hurvitz, co-principal investigator for the trial, said that the data for both combination treatments in the trials are “potentially practice-changing.” ...

Celcuity said its Phase 3 clinical trial evaluating gedatolisib resulted in positive topline results. The clinical-stage biotechnology company's trial evaluated gedatolisib plus fulvestrant with and ...

But for those taking fulvestrant and a placebo, cancer returned in an average of five months, the study found. Side effects were more common in the group taking the new drug combo, however.

The Food and Drug Administration (FDA) has approved Truqap ™ (capivasertib) in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal ...

Fulvestrant reduced risk of progression by 20% and extended median progression-free survival beyond anastrozole October 08, 2016 08:00 AM Eastern Daylight Time ...

The addition of dalpiciclib to fulvestrant appeared effective and safe for certain patients with advanced breast cancer, according to randomized phase 3 study results presented during the virtual ...

For fulvestrant to work well, the cells must also be responsive to estrogen, and producing the estrogen receptor ER-alpha. ER-alpha's importance to fulvestrant's anti-estrogenic action had been ...